← Back to Search

Anti-metabolites

Rituximab for Acute Leukemia

Phase 2

Waitlist Available

Led By Elias Jabbour

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 months

Awards & highlights

Study Summary

This trial is testing how well a combination of 5 different drugs work in treating patients with mixed phenotype acute leukemia.

Eligible Conditions

Acute Leukemia
Biphenotypic Leukemia
Acute Undifferentiated Leukemia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Participants Complete Response

Secondary outcome measures

4-week Mortality Rate

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (combination chemotherapy)Experimental Treatment9 Interventions

See Detailed Description.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cytarabine

FDA approved

Rituximab

FDA approved

Clofarabine

FDA approved

Sorafenib

FDA approved

Idarubicin

FDA approved

Vincristine

FDA approved

Sorafenib

FDA approved

Vincristine

FDA approved

Dexamethasone

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,966 Previous Clinical Trials

1,804,765 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,932,307 Total Patients Enrolled

Elias JabbourPrincipal InvestigatorM.D. Anderson Cancer Center

16 Previous Clinical Trials

1,012 Total Patients Enrolled

Media Library

Clofarabine (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT02135874 — Phase 2

Acute Leukemia Research Study Groups: Treatment (combination chemotherapy)

Acute Leukemia Clinical Trial 2023: Clofarabine Highlights & Side Effects. Trial Name: NCT02135874 — Phase 2

Clofarabine (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02135874 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many patients are being recruited for this trial?

"The clinical trial is recruiting patients, as shown by the information on clinicaltrials.gov. This study was first posted on 27 October 2014 and updated on 18 August 2022. They are looking for 60 people to participate at 1 site."

Answered by AI

What conditions does Rituximab usually treat?

"Rituximab can help patients that are struggling with ophthalmia, sympathetic, refractory langerhans cell histiocytosis, and branch retinal vein occlusion."

Answered by AI

To what other conditions has Rituximab been applied in research?

"There are currently 1324 active clinical trials for the use of rituximab. Of these, 337 studies are in Phase 3 testing. Most trials for rituximab are taking place Mishawaka, Indiana; however, there are a total of 47261 locations running trials with this medication."

Answered by AI

Has the Federal Drug Administration cleared Rituximab for public use?

"Rituximab is a medication that has undergone Phase 2 clinical trials. While there is some evidence backing its safety, more research needs to be conducted to support its efficacy."

Answered by AI

Are doctors currently looking for new patients to enroll in this clinical trial?

"That is accurate. According to the clinicaltrials.gov listing, this experiment was most recently updated on 8/18/2022 and is presently looking for 60 individuals from 1 location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

2014. "Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02135874.